Korro Bio, Inc. announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer, effective May 13, 2024. Prior to joining Korro, Dr. Olugemo, age 48, served as Vice President of Global Clinical Development at Ultragenyx Pharmaceutical Inc. from December 2022 to May 2024. Prior to this role, she served as Head of Clinical Development at Laronde, Inc. from November 2021 to December 2022 and as Executive Director of Clinical Development at Ionis Pharmaceuticals Inc. from November 2019 to November 2021.

Dr. Olugemo also served as Senior Director of Global Therpeutic Area Head, Neuroscience at Parexel International Corp. from June 2014 to November 2019. Dr. Olugemo led clinical development and operations for multiple global programs in rare and common diseases across an array of therapeutic areas, resulting in approvals in global markets.

Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and completed her Neurology Residency there. Dr. Olugemo also completed an additional Fellowship in Neuroimmunology & Multiple Sclerosis at the Maryland Center for Multiple Sclerosis. She holds a B.S. in clinical laboratory science from the University of Massachusetts.